Linked Life Data

8383651

Source:http://linkedlifedata.com/resource/pubmed/id/8383651

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1993-4-12
pubmed:abstractText
The efficacy and safety of piperacillin in combination with the beta-lactamase inhibitor tazobactam were assessed in an open, multi-centre study of hospitalized patients with skin and soft tissue infections. A total of 136 patients from four countries were treated with piperacillin 4 g plus tazobactam 500 mg every 8 h. The mean duration of treatment was eight days. Clinical and bacteriological evaluations were performed one to three days and ten to 14 days post-therapy, respectively. Among 120 evaluable patients 93% were clinically cured or improved; 91% of bacteriologically evaluable patients were cured or improved. Eradication of the pathogens was observed in 85% and 95% of the evaluable patients at first and second follow-up. In 43% of the patients more than one pathogen was isolated from the wound. Persistence was commonest in patients in whom a complete surgical debridement could not be carried out. There were adverse events in 16 of the 136 patients, most commonly allergic reactions and diarrhoea. Six patients were withdrawn from the study because of side-effects.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0305-7453
pubmed:author
pubmed:issnType
Print
pubmed:volume
31 Suppl A
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
105-12
pubmed:dateRevised
2005-11-17
pubmed:meshHeading
pubmed:year
1993
pubmed:articleTitle
Therapy of soft tissue infections with piperacillin/tazobactam.
pubmed:affiliation
Dortmund Accident Surgery Clinic, Germany.
pubmed:publicationType
Journal Article